Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Queensland Health
Teva
Colorcon
Federal Trade Commission
Harvard Business School
Healthtrust
McKinsey
Novartis
Citi

Generated: February 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,408,858

« Back to Dashboard

Summary for Patent: 9,408,858
Title:Method for treating secondary hyperparathyroidism in CKD
Abstract: A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.
Inventor(s): Bishop; Charles W. (Miami Beach, FL), Tabash; Samir P. (Whitby, CA), Agudoawu; Sammy A. (Mississauga, CA), White; Jay A. (Newmarket, CA), Crawford; Keith H. (Highlands Ranch, CO), Messner; Eric J. (Lake Forest, IL), Petkovich; P. Martin (Kingston, CA)
Assignee: OPKO RENAL, LLC (Miami, FL) OPKO IRELAND GLOBAL HOLDINGS, LTD. (Grand Cayman, KY)
Application Number:14/690,131
Patent Claim Types:
see list of patent claims
Use; Dosage form; Composition;

Drugs Protected by US Patent 9,408,858

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Opko Ireland Global RAYALDEE calcifediol CAPSULE, EXTENDED RELEASE;ORAL 208010-001 Jun 17, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial USE OF CONTROLLED RELEASE 25-HYDROXYVITAMIN D IN TREATING SECONDARY HYPERPARATHYROIDISM IN PATIENTS HAVING CHRONIC KIDNEY DISEASE ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,408,858

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,207,149 Method for treating secondary hyperparathyroidism in CKD ➤ Try a Free Trial
9,498,486 Method for controlled release oral dosage of a vitamin D compound ➤ Try a Free Trial
8,361,488 Methods and compositions for controlled release oral dosage of a vitamin D compound ➤ Try a Free Trial
8,778,373 Methods for controlled release oral dosage of a vitamin D compound ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,408,858

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia 2481400 ➤ Try a Free Trial
Slovenia 2148661 ➤ Try a Free Trial
Portugal 2481400 ➤ Try a Free Trial
Portugal 2148661 ➤ Try a Free Trial
South Korea 20170085141 ➤ Try a Free Trial
South Korea 101759244 ➤ Try a Free Trial
South Korea 20170004018 ➤ Try a Free Trial
South Korea 101691876 ➤ Try a Free Trial
South Korea 20140131603 ➤ Try a Free Trial
South Korea 101540369 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Farmers Insurance
Covington
Boehringer Ingelheim
Fish and Richardson
Fuji
Mallinckrodt
Citi
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot